Academic Journal
Προβολή σε EDS

Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.
Συγγραφείς: Wang X; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China., Zhou D; Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.; Jiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, China., Li M; College of Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China., Kong X; Endocrinology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China., Jiang S; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China., Li Q; Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China., Wei L; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China., Jiang L; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China., Song W; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.
Πηγή: Virulence [Virulence] 2026 Dec; Vol. 17 (1), pp. 2712031. Date of Electronic Publication: 2026 Aug 03.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE
Imprint Name(s): Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
Ιατρικοί όροι (MeSH): Luteolin*/pharmacology , Urease*/antagonists & inhibitors , Urease*/chemistry , Helicobacter pylori*/drug effects , Helicobacter pylori*/enzymology , Helicobacter Infections*/drug therapy , Helicobacter Infections*/microbiology , Enzyme Inhibitors*/pharmacology , Anti-Bacterial Agents*/pharmacology, Bacterial Proteins/antagonists & inhibitors ; Animals ; Mice ; Humans ; Molecular Docking Simulation ; Cell Line ; Disease Models, Animal
Περίληψη: The rising prevalence of antibiotic-resistant Helicobacter pylori (H. pylori) underscores the urgent need for alternative treatment strategies. By producing ammonia to neutralize gastric acid, the key virulence factor urease is essential for H. pylori acid tolerance, thereby representing a promising therapeutic target. In this study, we identified luteolin as a potent urease inhibitor (IC50 = 30.50 μg/mL) from a screening of over 200 natural compounds. Further investigation through molecular docking, dynamics simulations, cellular thermal shift assay, and enzyme kinetics studies confirmed its competitive binding to the Ni2+-centered catalytic site of H. pylori urease (HPU). Luteolin exhibited potent anti-H. pylori activity under standard and simulated gastric conditions, and showed low propensity for resistance development over 14 serial passages. Proteomic and metabolomic analyses revealed that luteolin inhibited HPU activity, and the consequent ammonia restriction triggered severe metabolic dysfunction, characterized by disruptions in nucleotide, amino acid biosynthesis and TCA cycle. In GES-1 cells, luteolin protected against H. pylori-induced damage. In a mouse model of H. pylori-induced peptic ulcer, luteolin treatment significantly reduced the bacterial load, with concomitant alleviation of gastric mucosal pathology and suppression of inflammatory responses. In contrast to antibiotic-induced gastric microbial dysbiosis, microbial diversity analysis indicated that luteolin treatment had minimal impact on the resident gastric microbiota. In summary, as a urease inhibitor, luteolin suppresses H. pylori by blocking ammonia production, thereby disrupting acid neutralization and inducing metabolic dysfunction, which collectively alleviates gastric damage and inflammation while minimizing microbiota disruption and resistance risk.
References: Nat Rev Dis Primers. 2023 Apr 20;9(1):19. (PMID: 37081005)
Nat Rev Cancer. 2010 Jun;10(6):403-14. (PMID: 20495574)
Anal Cell Pathol (Amst). 2019 Apr 4;2019:9506863. (PMID: 31093484)
Front Pharmacol. 2024 Jun 24;15:1430564. (PMID: 38983919)
Int J Mol Sci. 2025 Jun 22;26(13):. (PMID: 40649776)
Biochem Biophys Res Commun. 2003 Oct 24;310(3):715-9. (PMID: 14550260)
Eur J Pharm Sci. 2024 Sep 1;200:106840. (PMID: 38909691)
Dig Dis Sci. 2017 May;62(5):1146-1154. (PMID: 28315035)
Biomed Rep. 2021 Feb;14(2):19. (PMID: 33335725)
J Chem Inf Model. 2022 Aug 8;62(15):3535-3550. (PMID: 35666858)
Infect Immun. 1994 Aug;62(8):3586-9. (PMID: 8039935)
Nucleic Acids Res. 2024 Jul 5;52(W1):W422-W431. (PMID: 38572755)
J Ethnopharmacol. 2018 Oct 28;225:342-358. (PMID: 29801717)
J Agric Food Chem. 2010 Oct 13;58(19):10661-7. (PMID: 20853834)
Drug Metab Pharmacokinet. 2012;27(1):162-8. (PMID: 21931223)
Exp Ther Med. 2014 Sep;8(3):769-774. (PMID: 25120597)
Nature. 2013 Jan 10;493(7431):255-8. (PMID: 23222544)
J Agric Food Chem. 2015 Sep 9;63(35):7700-6. (PMID: 25625345)
J Enzyme Inhib Med Chem. 2020 Dec;35(1):404-413. (PMID: 31880473)
Expert Opin Ther Pat. 2011 Jun;21(6):945-57. (PMID: 21457123)
Antioxidants (Basel). 2024 Dec 13;13(12):. (PMID: 39765858)
Microb Pathog. 2025 Jul;204:107519. (PMID: 40164399)
Helicobacter. 2024 Jul-Aug;29(4):e13130. (PMID: 39152663)
BMC Med. 2024 Dec 23;22(1):598. (PMID: 39710669)
Eur Urol. 1991;20(3):243-7. (PMID: 1726639)
Lab Invest. 2009 Nov;89(11):1291-303. (PMID: 19736546)
FEMS Immunol Med Microbiol. 1996 Jan;13(1):87-94. (PMID: 8821403)
Helicobacter. 2022 Dec;27(6):e12932. (PMID: 36110057)
J Ethnopharmacol. 2024 Jan 10;318(Pt B):117046. (PMID: 37586440)
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1362-1375. (PMID: 30191728)
Front Microbiol. 2016 Nov 22;7:1817. (PMID: 27920755)
Microbiology (Reading). 2025 Mar;171(3):. (PMID: 40072906)
J Ethnopharmacol. 2022 Sep 15;295:115388. (PMID: 35577159)
Gut. 2017 Jan;66(1):6-30. (PMID: 27707777)
Sci Rep. 2018 May 22;8(1):8014. (PMID: 29789574)
Antimicrob Agents Chemother. 2017 May 24;61(6):. (PMID: 28320722)
Sci Rep. 2024 Jul 7;14(1):15619. (PMID: 38972876)
Lancet Gastroenterol Hepatol. 2024 Jan;9(1):56-67. (PMID: 37972625)
J Ethnopharmacol. 2025 Apr 09;345:119569. (PMID: 40054639)
Int Immunopharmacol. 2023 Feb;115:109679. (PMID: 36640711)
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0024022. (PMID: 35862746)
Folia Microbiol (Praha). 2020 Apr;65(2):275-291. (PMID: 32026288)
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):317-23. (PMID: 22697063)
Int J Med Microbiol. 2024 Jun;315:151622. (PMID: 38776570)
Infect Genet Evol. 2020 Mar;78:104135. (PMID: 31837482)
Mol Microbiol. 2018 Dec;110(5):761-776. (PMID: 30230643)
Evid Based Complement Alternat Med. 2022 May 9;2022:4476339. (PMID: 35586693)
J Adv Res. 2018 Jan 31;13:51-57. (PMID: 30094082)
Sci Adv. 2020 Jul 22;6(30):eaay9597. (PMID: 32832655)
Cochrane Database Syst Rev. 2016 Apr 19;4:CD003840. (PMID: 27092708)
Front Med (Lausanne). 2022 Mar 24;9:844915. (PMID: 35402425)
Nucleic Acids Res. 2024 Jul 5;52(W1):W324-W332. (PMID: 38686803)
AAPS PharmSciTech. 2021 Apr 14;22(3):133. (PMID: 33855636)
J Cancer Prev. 2014 Jun;19(2):144-51. (PMID: 25337583)
Int J Biol Sci. 2025 May 7;21(8):3397-3415. (PMID: 40520011)
Chem Sci. 2018 Jul 25;9(38):7488-7497. (PMID: 30510674)
Contributed Indexing: Keywords: Helicobacter pylori; ammonia restriction; luteolin; metabolic disruption; urease
Substance Nomenclature: KUX1ZNC9J2 (Luteolin)
EC 3.5.1.5 (Urease)
0 (Enzyme Inhibitors)
0 (Anti-Bacterial Agents)
0 (Bacterial Proteins)
Entry Date(s): Date Created: 20260804 Date Completed: 20260804 Latest Revision: 20260813
Update Code: 20260814
PubMed Central ID: PMC13449824
DOI: 10.1080/21505594.2026.2712031
PMID: 42548046
Βάση Δεδομένων: MEDLINE
καταχωρήστε σχόλιο πρώτοι!
Πρέπει πρώτα να συνδεθείτε